MCK · McKesson Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $403.43B | $359.05B | $308.95B | $276.71B | $263.97B | $238.23B |
| Cost of Revenue | $388.88B | $345.73B | $296.12B | $264.35B | $250.84B | $226.08B |
| Gross Profit | $14.55B | $13.32B | $12.83B | $12.36B | $13.13B | $12.15B |
| R&D | - | - | - | - | - | - |
| SG&A | $8.10B | $8.51B | $8.66B | $7.78B | $10.54B | $8.85B |
| Total Operating Expenses | $8.34B | $8.90B | $8.92B | $7.98B | $11.09B | $17.19B |
| D&A | $287.00M | $272.00M | $279.00M | $272.00M | $312.00M | $335.00M |
| Operating Income | $6.21B | $4.42B | $3.91B | $4.38B | $2.04B | ($5.04B) |
| Interest Expense | $247.00M | $252.00M | $252.00M | $248.00M | $178.00M | $217.00M |
| Income Tax | $1.10B | $878.00M | $629.00M | $905.00M | $636.00M | ($695.00M) |
| Net Income | $4.76B | $3.29B | $3.00B | $3.56B | $1.11B | ($4.54B) |
| EPS - Basic | $38.55 | $25.86 | $22.54 | $25.23 | $7.32 | ($28.26) |
| EPS - Diluted | $38.38 | $25.72 | $22.39 | $25.03 | $7.23 | ($28.26) |
Balance Sheet
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.98B | $5.69B | $4.58B | $4.68B | $3.53B | $6.28B |
| Accounts Receivable | $27.98B | $25.64B | $21.62B | $19.41B | $18.58B | $19.18B |
| Inventory | $24.21B | $23.00B | $21.14B | $19.69B | $18.70B | $19.25B |
| Accounts Payable | $59.97B | $55.33B | $47.10B | $42.49B | $38.09B | $38.98B |
| Current Assets | $57.21B | $55.40B | $47.97B | $44.29B | $46.23B | $45.38B |
| Total Assets | $82.32B | $75.14B | $67.44B | $62.32B | $63.30B | $65.02B |
| Current Liabilities | $67.02B | $61.60B | $52.36B | $47.96B | $48.47B | $44.10B |
| Long-term Debt | $6.53B | $5.65B | $5.63B | $5.59B | $5.88B | $7.15B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($2.17B) | ($2.07B) | ($1.97B) | ($1.86B) | ($2.27B) | ($21.00M) |
| Retained Earnings | $22.29B | $17.92B | $14.98B | $12.29B | $9.03B | $8.20B |
Cash Flow
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.16B | $6.08B | $4.31B | $5.16B | $4.43B | $4.54B |
| Investing Cash Flow | ($3.43B) | ($733.00M) | ($1.07B) | ($542.00M) | ($89.00M) | ($415.00M) |
| Financing Cash Flow | ($4.63B) | ($3.96B) | ($3.34B) | ($4.37B) | ($6.32B) | ($1.69B) |
| CapEx | $436.00M | $537.00M | $431.00M | $390.00M | $388.00M | $451.00M |
| Free Cash Flow | $5.72B | $5.55B | $3.88B | $4.77B | $4.05B | $4.09B |
Ratios
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 3.6% | 3.7% | 4.2% | 4.5% | 5.0% | 5.1% |
| Operating margin | 1.5% | 1.2% | 1.3% | 1.6% | 0.8% | -2.1% |
| EBITDA margin | 1.6% | 1.3% | 1.4% | 1.7% | 0.9% | -2.0% |
| Net margin | 1.2% | 0.9% | 1.0% | 1.3% | 0.4% | -1.9% |
| Free cash flow margin | 1.4% | 1.5% | 1.3% | 1.7% | 1.5% | 1.7% |
| FCF / Net income | 1.20 | 1.68 | 1.29 | 1.34 | 3.63 | -0.90 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 2.0% | 2.4% | 2.8% | 2.8% | 4.0% | 3.7% |
| Effective tax rate | 18.8% | 21.0% | 17.3% | 20.3% | 36.3% | - |
| Return on assets | 5.8% | 4.4% | 4.5% | 5.7% | 1.8% | -7.0% |
| Return on equity | -219.2% | -158.9% | -152.3% | -191.7% | -49.0% | 21614.3% |
| Return on invested capital | 115.9% | 97.5% | 88.3% | 93.5% | 36.0% | -55.9% |
| Liquidity | ||||||
| Current ratio | 0.85 | 0.90 | 0.92 | 0.92 | 0.95 | 1.03 |
| Quick ratio | 0.49 | 0.53 | 0.51 | 0.51 | 0.57 | 0.59 |
| Cash ratio | 0.06 | 0.09 | 0.09 | 0.10 | 0.07 | 0.14 |
| Leverage | ||||||
| Debt / Equity | -3.00 | -2.73 | -2.86 | -3.01 | -2.59 | -340.38 |
| Debt / Assets | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.11 |
| Debt / EBITDA | 1.00 | 1.20 | 1.34 | 1.20 | 2.50 | - |
| Interest coverage | 25.1x | 17.5x | 15.5x | 17.7x | 11.4x | -23.2x |
| Equity multiplier | -37.90 | -36.23 | -34.22 | -33.56 | -27.86 | -3095.95 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 4.90 | 4.78 | 4.58 | 4.44 | 4.17 | 3.66 |
| Inventory turnover | 16.06 | 15.03 | 14.01 | 13.43 | 13.41 | 11.75 |
| Days sales outstanding | 25d | 26d | 26d | 26d | 26d | 29d |
| Days inventory outstanding | 23d | 24d | 26d | 27d | 27d | 31d |
| Days payable outstanding | 56d | 58d | 58d | 59d | 55d | 63d |
| Cash conversion cycle | -8d | -8d | -6d | -6d | -3d | -2d |
| Valuation | ||||||
| P / E | 22.5x | 26.2x | 24.0x | 14.2x | 42.3x | - |
| P / B | - | - | - | - | - | - |
| P / S | 0.3x | 0.2x | 0.2x | 0.2x | 0.2x | 0.1x |
| EV / EBITDA | 16.9x | 18.4x | 17.4x | 11.1x | 21.1x | - |
| Growth | ||||||
| Revenue growth (YoY) | 12.4% | 16.2% | 11.7% | 4.8% | 10.8% | 3.1% |
| Revenue CAGR (3y) | 13.4% | 10.8% | 9.1% | 6.2% | 10.0% | 4.6% |
| Revenue CAGR (5y) | 11.1% | 9.2% | 9.2% | 5.8% | 5.9% | 4.5% |
| Gross profit growth (YoY) | 9.2% | 3.9% | 3.8% | -5.9% | 8.1% | 1.0% |
| Operating income growth (YoY) | 40.5% | 13.1% | -10.8% | 115.0% | - | - |
| Net income growth (YoY) | 44.5% | 9.8% | -15.7% | 219.6% | - | - |
| EPS growth (YoY) | 49.2% | 14.9% | -10.5% | 246.2% | - | - |
| EPS CAGR (3y) | 15.3% | 52.7% | - | 71.6% | 249.1% | - |
| EPS CAGR (5y) | - | 39.0% | 165.4% | 139.1% | -20.5% | - |
| FCF growth (YoY) | 3.1% | 42.9% | -18.6% | 17.9% | -1.1% | 2.0% |
| FCF CAGR (5y) | 6.9% | 6.7% | 1.5% | 3.9% | -1.4% | 5.1% |
| Book value growth (YoY) | -4.7% | -5.2% | -6.1% | 18.3% | -10719.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-31.
Business segments
$67.33B totalOncology And Multispecialty Segment$48.42B · 71.9%
Medical Surgical Solutions Segment$11.51B · 17.1%
Prescription Technology Solutions Segment$5.80B · 8.6%
North American Pharmaceutical Segment$1.60B · 2.4%
Stability scores
Piotroski F-score
FY 2026 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing MCKESSON CORP against the 5 most active filers in the same SIC group.
Dividends
$3.28/share trailing 12 months · +15.5% YoY
| Ex-date | Per share |
|---|---|
| Jun 1, 2026 | $0.8200 |
| Mar 2, 2026 | $0.8200 |
| Dec 1, 2025 | $0.8200 |
| Sep 2, 2025 | $0.8200 |
| Jun 2, 2025 | $0.7100 |
| Mar 3, 2025 | $0.7100 |
| Dec 2, 2024 | $0.7100 |
| Aug 30, 2024 | $0.7100 |
| Jun 3, 2024 | $0.6200 |
| Feb 29, 2024 | $0.6200 |
| Nov 30, 2023 | $0.6200 |
| Aug 31, 2023 | $0.6200 |
| May 31, 2023 | $0.5400 |
| Feb 28, 2023 | $0.5400 |
| Nov 30, 2022 | $0.5400 |
| Aug 31, 2022 | $0.5400 |
| May 31, 2022 | $0.4700 |
| Feb 28, 2022 | $0.4700 |
| Nov 30, 2021 | $0.4700 |
| Aug 31, 2021 | $0.4700 |
| May 28, 2021 | $0.4200 |
| Mar 1, 2021 | $0.4200 |
| Nov 30, 2020 | $0.4200 |
| Aug 31, 2020 | $0.4200 |